QGEN stock: Allocaria Score and valuation gap
As of 26.10.2026, QIAGEN NV (QGEN) has an Allocaria Score of 69 out of 100, which reads as “Good”. The price sits 2.6% below the model’s fair-value estimate. An estimate, not a price target.
QIAGEN NV · Health Care · Netherlands · large-cap company
Allocaria Score and gap to the model’s fair-value estimate
Allocaria Score
69 out of 100
Good Ratings as of 26.10.2026
A relative score on current evidence — not a probability, a price forecast or a guarantee.
Gap to the model’s fair-value estimate
+2.6%
The price sits 2.6% below the model’s fair-value estimate. An estimate, not a price target.
A positive figure means the price is below the model’s estimate; a negative figure means it is above.
What moves the score
- Quality lifts the score
- Quality (composite) lifts the score
Why: the two parts of the score that push it furthest from neutral — + lifts it, − lowers it. Nothing is shown when no part stands out.
Health Care in Allocaria’s coverage
QIAGEN NV ranks 126th of 482 Health Care companies in Allocaria’s coverage by Allocaria Score; the sector median is 56 out of 100.
Other Health Care companies
Questions about this page
QIAGEN NV has an Allocaria Score of 69 out of 100 as of 26.10.2026, which reads as “Good”. A relative score on current evidence — not a probability, a price forecast or a guarantee.
The price sits 2.6% below the model’s fair-value estimate. An estimate, not a price target. A positive figure means the price is below the model’s estimate; a negative figure means it is above.
It helps a self-directed investor decide what to study further and what to set aside. A rank is not a probability and not an order.
It shows the ratings as of 26.10.2026. The page is refreshed when the ratings are, and it is withdrawn when the data is older than about six weeks.